Danaher Corporation has appointed Greg Milosevich as executive vice president of its Life Sciences business.

Milosevich has been vice president and group executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to President/CEO Rainer Blair.

“Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past four years,” Blair stated. “His consistent ability to deliver results, deep customer focus and talent for building high-performing teams—combined with his strong embodiment of the Danaher Business System—make him an outstanding leader. I’m confident he will continue to drive success as he takes on this expanded role.”

Milosevich joined Danaher in 2010 through the acquisition of Molecular Devices, and since has held roles of increasing responsibility across multiple businesses. In his most recent role—vice president and group executive, Life Sciences Innovations Group—Milosevich managed multiple Danaher companies, including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS, and Genedata.

Milosevich earned a bachelor’s degree in physics from the University of Puget Sound, graduating Summa Cum Laude.

Danaher is a global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Its advanced science and technology, and ability to innovate, help enable faster, more accurate diagnoses and reduce the time and cost needed to sustainably discover, develop, and deliver life-changing therapies. The company’s 63,000 associates worldwide help ensure that Danaher is improving quality of life for people.

This article by one of our Danaher Life Sciences thought leaders was originally published in Medical Product Outsourcing. Shared here by permission.